Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 2Breast Neoplasms 2Overweight 1Obesity 1Melanoma 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Tamoxifen 12Specimen Handling 6Anastrozole 6Chemotherapy, Adjuvant 5Radiotherapy 4Letrozole 4afimoxifene 3Mastectomy, Segmental 3Surgical Procedures, Operative 2Simvastatin 2Radiation Dose Hypofractionation 2Radiation 2Fish Oils 2Fatty Acids, Omega-3 24,17 beta-dihydroxy-4-androstene-3-one 2telapristone acetate 1sargramostim 1ruxolitinib 1polyphenon E 1palbociclib 1fezolinetant 1exemestane 1elacestrant 1darolutamide 1bazedoxifene 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1abemaciclib 1Zoledronic Acid 1Testosterone 1Tea 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Intraductal, Noninfiltrating × Naltrexone × Clear all
NCT02137252 2021-11-16

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Terminated
3 enrolled 4 charts
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡